Combination of serum PSA assay, multi-parametric MRI and targeted prostate biopsy for prostate cancer screening in Nanjing

To investigate the exact prevalence of PCa among males in Nanjing and search for a mode of PCa screening suitable for the specific conditions. From January to December 2018, we collected serum samples and clinical information from 6 903 men aged ≥50 years taking physical examination in 16 community...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Zhonghua nan ke xue Ročník 25; číslo 9; s. 815
Hlavní autoři: Liang, Jing, Zhao, Xiao-Zhi, Shi, Jing-Yan, Qiu, Xue-Feng, Zhang, Qing, Zhuang, Jun-Long, Wang, Wei, Deng, Yong-Ming, Huang, Hai-Feng, Zhang, Cheng-Wei, Guo, Hong-Qian
Médium: Journal Article
Jazyk:čínština
Vydáno: China 01.09.2019
Témata:
Biopsy
China
Early Detection of Cancer - methods
Humans
Image-Guided Biopsy
Magnetic Resonance Imaging
Male
Middle Aged
Prevalence
Prostate-Specific Antigen - blood
Prostatic Neoplasms - diagnosis
Prostatic Neoplasms - epidemiology
China
Nanjing area
multi-parametric MRI
MRI/ultrasound fusion biopsy
prostate cancer screening
prostate-specific antigen
ISSN:1009-3591
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Abstract To investigate the exact prevalence of PCa among males in Nanjing and search for a mode of PCa screening suitable for the specific conditions. From January to December 2018, we collected serum samples and clinical information from 6 903 men aged ≥50 years taking physical examination in 16 community health service centers in Nanjing. We proposed multi-parametric MRI (mpMRI) for those with serum PSA ≥4 μg/L, transperineal systematic biopsy and MRI/ultrasound fusion targeted prostate biopsy for those who scored ≥3 points on the Prostate Imaging-Reporting and Data System Version 2 (PI-RADS v2), transperineal systematic biopsy only for those with a PI-RADS v2 score of <3 and serum PSA ≥10 μg/L, and follow-up examinations every 6 months for those with a PI-RADS v2 score of <3 and serum PSA <4 μg/L. Among the 6 903 male subjects, 835 (12.1%) were found with serum PSA≥4 μg/L; 229 (77.4%) of the 296 men that received mpMRI scored ≥3 points on PI-RADS v2; and 79 (53.4%) of the 148 males that underwent prostate biopsy w
AbstractList To investigate the exact prevalence of PCa among males in Nanjing and search for a mode of PCa screening suitable for the specific conditions.OBJECTIVETo investigate the exact prevalence of PCa among males in Nanjing and search for a mode of PCa screening suitable for the specific conditions.From January to December 2018, we collected serum samples and clinical information from 6 903 men aged ≥50 years taking physical examination in 16 community health service centers in Nanjing. We proposed multi-parametric MRI (mpMRI) for those with serum PSA ≥4 μg/L, transperineal systematic biopsy and MRI/ultrasound fusion targeted prostate biopsy for those who scored ≥3 points on the Prostate Imaging-Reporting and Data System Version 2 (PI-RADS v2), transperineal systematic biopsy only for those with a PI-RADS v2 score of <3 and serum PSA ≥10 μg/L, and follow-up examinations every 6 months for those with a PI-RADS v2 score of <3 and serum PSA <4 μg/L.METHODSFrom January to December 2018, we collected serum samples and cl
To investigate the exact prevalence of PCa among males in Nanjing and search for a mode of PCa screening suitable for the specific conditions. From January to December 2018, we collected serum samples and clinical information from 6 903 men aged ≥50 years taking physical examination in 16 community health service centers in Nanjing. We proposed multi-parametric MRI (mpMRI) for those with serum PSA ≥4 μg/L, transperineal systematic biopsy and MRI/ultrasound fusion targeted prostate biopsy for those who scored ≥3 points on the Prostate Imaging-Reporting and Data System Version 2 (PI-RADS v2), transperineal systematic biopsy only for those with a PI-RADS v2 score of <3 and serum PSA ≥10 μg/L, and follow-up examinations every 6 months for those with a PI-RADS v2 score of <3 and serum PSA <4 μg/L. Among the 6 903 male subjects, 835 (12.1%) were found with serum PSA≥4 μg/L; 229 (77.4%) of the 296 men that received mpMRI scored ≥3 points on PI-RADS v2; and 79 (53.4%) of the 148 males that underwent prostate biopsy w
Author Zhang, Cheng-Wei
Qiu, Xue-Feng
Wang, Wei
Shi, Jing-Yan
Guo, Hong-Qian
Liang, Jing
Zhao, Xiao-Zhi
Zhuang, Jun-Long
Zhang, Qing
Deng, Yong-Ming
Huang, Hai-Feng
Author_xml – sequence: 1
  givenname: Jing
  surname: Liang
  fullname: Liang, Jing
  organization: Department of Urology / Nanjing University Research Institute of Urology, Nanjing Drum Tower Hospital, Nanjing University School of Medicine, Nanjing, Jiangsu 210008, China
– sequence: 2
  givenname: Xiao-Zhi
  surname: Zhao
  fullname: Zhao, Xiao-Zhi
  organization: Department of Urology / Nanjing University Research Institute of Urology, Nanjing Drum Tower Hospital, Nanjing University School of Medicine, Nanjing, Jiangsu 210008, China
– sequence: 3
  givenname: Jing-Yan
  surname: Shi
  fullname: Shi, Jing-Yan
  organization: Department of Urology / Nanjing University Research Institute of Urology, Nanjing Drum Tower Hospital, Nanjing University School of Medicine, Nanjing, Jiangsu 210008, China
– sequence: 4
  givenname: Xue-Feng
  surname: Qiu
  fullname: Qiu, Xue-Feng
  organization: Department of Urology / Nanjing University Research Institute of Urology, Nanjing Drum Tower Hospital, Nanjing University School of Medicine, Nanjing, Jiangsu 210008, China
– sequence: 5
  givenname: Qing
  surname: Zhang
  fullname: Zhang, Qing
  organization: Department of Urology / Nanjing University Research Institute of Urology, Nanjing Drum Tower Hospital, Nanjing University School of Medicine, Nanjing, Jiangsu 210008, China
– sequence: 6
  givenname: Jun-Long
  surname: Zhuang
  fullname: Zhuang, Jun-Long
  organization: Department of Urology / Nanjing University Research Institute of Urology, Nanjing Drum Tower Hospital, Nanjing University School of Medicine, Nanjing, Jiangsu 210008, China
– sequence: 7
  givenname: Wei
  surname: Wang
  fullname: Wang, Wei
  organization: Department of Urology / Nanjing University Research Institute of Urology, Nanjing Drum Tower Hospital, Nanjing University School of Medicine, Nanjing, Jiangsu 210008, China
– sequence: 8
  givenname: Yong-Ming
  surname: Deng
  fullname: Deng, Yong-Ming
  organization: Department of Urology / Nanjing University Research Institute of Urology, Nanjing Drum Tower Hospital, Nanjing University School of Medicine, Nanjing, Jiangsu 210008, China
– sequence: 9
  givenname: Hai-Feng
  surname: Huang
  fullname: Huang, Hai-Feng
  organization: Department of Urology / Nanjing University Research Institute of Urology, Nanjing Drum Tower Hospital, Nanjing University School of Medicine, Nanjing, Jiangsu 210008, China
– sequence: 10
  givenname: Cheng-Wei
  surname: Zhang
  fullname: Zhang, Cheng-Wei
  organization: Department of Urology / Nanjing University Research Institute of Urology, Nanjing Drum Tower Hospital, Nanjing University School of Medicine, Nanjing, Jiangsu 210008, China
– sequence: 11
  givenname: Hong-Qian
  surname: Guo
  fullname: Guo, Hong-Qian
  organization: Department of Urology / Nanjing University Research Institute of Urology, Nanjing Drum Tower Hospital, Nanjing University School of Medicine, Nanjing, Jiangsu 210008, China
BackLink https://www.ncbi.nlm.nih.gov/pubmed/32233209$$D View this record in MEDLINE/PubMed
BookMark eNpFUMlqwzAU1CGlSdP8QtGxhxpkyZajYwhdAulCl7N5kp-Dii25knxIv76GpvQ0C8MwzAWZOe9wRhY5YyoTpcrnZBWj1YzlPC-5UudkLjgXgjO1IN9b32vrIFnvqG9pxDD29OVtQyFGON7QfuySzQYI0GMK1tDH1x0F19AE4YAJGzoEHxMkpNr6IR5p68O_Z8AZDDSagOisO1Dr6BO4z4lekrMWuoirEy7Jx93t-_Yh2z_f77abfTbkXKZMMrVupeRtDihYK6Fo1CR5oVBzaEqzLhUzVVVKwQvEEhupq0IXSkiRM2B8Sa5_e6dRXyPGVPc2Guw6cOjHWHOxLnk1fVNN0atTdNQ9NvUQbA_hWP_9xX8AgpZo8A
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
ExternalDocumentID 32233209
Genre Journal Article
GeographicLocations China
GeographicLocations_xml – name: China
GroupedDBID ---
-05
92F
92I
ABJNI
ACGFS
ALMA_UNASSIGNED_HOLDINGS
CCEZO
CGR
CIEJG
CUY
CVF
CW9
ECM
EIF
EMOBN
F5P
NPM
SV3
TCJ
TGQ
U1G
U5O
7X8
ID FETCH-LOGICAL-p126t-6098f662f1ae30f6a4d9662249eb2ad5c8590c7756324ee5ed6b74b4936310a02
IEDL.DBID 7X8
ISSN 1009-3591
IngestDate Fri Jul 11 02:18:48 EDT 2025
Mon Jul 21 05:54:10 EDT 2025
IsPeerReviewed false
IsScholarly false
Issue 9
Keywords Nanjing area
multi-parametric MRI
MRI/ultrasound fusion biopsy
prostate cancer screening
prostate-specific antigen
Language Chinese
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-p126t-6098f662f1ae30f6a4d9662249eb2ad5c8590c7756324ee5ed6b74b4936310a02
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 32233209
PQID 2385272157
PQPubID 23479
ParticipantIDs proquest_miscellaneous_2385272157
pubmed_primary_32233209
PublicationCentury 2000
PublicationDate 2019-Sep
20190901
PublicationDateYYYYMMDD 2019-09-01
PublicationDate_xml – month: 09
  year: 2019
  text: 2019-Sep
PublicationDecade 2010
PublicationPlace China
PublicationPlace_xml – name: China
PublicationTitle Zhonghua nan ke xue
PublicationTitleAlternate Zhonghua Nan Ke Xue
PublicationYear 2019
SSID ssib001215299
ssj0058533
ssib036442090
ssib008809553
ssib051368276
ssib051815678
ssib001103509
Score 1.8551911
Snippet To investigate the exact prevalence of PCa among males in Nanjing and search for a mode of PCa screening suitable for the specific conditions. From January to...
To investigate the exact prevalence of PCa among males in Nanjing and search for a mode of PCa screening suitable for the specific conditions.OBJECTIVETo...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage 815
SubjectTerms Biopsy
China
Early Detection of Cancer - methods
Humans
Image-Guided Biopsy
Magnetic Resonance Imaging
Male
Middle Aged
Prevalence
Prostate-Specific Antigen - blood
Prostatic Neoplasms - diagnosis
Prostatic Neoplasms - epidemiology
Title Combination of serum PSA assay, multi-parametric MRI and targeted prostate biopsy for prostate cancer screening in Nanjing
URI https://www.ncbi.nlm.nih.gov/pubmed/32233209
https://www.proquest.com/docview/2385272157
Volume 25
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3Pa9swFBbdssMu7Uq39cdWVOixZrZkWdaphLGyHhJCt0JuQb_MMqjtNkkh-ev7yXbmXAaDXYwx-CDp6Xvfp_f0HiGX2lnLs9xGkMgWAgVb0eRGRPD1ykqf-jx2TbMJOR7n06madAduiy6tcouJDVC7yoYz8i9wLYJBrgh5XT9GoWtUiK52LTRekQEHlQlWLac7UaAkxM126QO81Q79hu0q0bsrDm7A4j5qJBKMgvXuWiShtIr8E6UA0-ZtAn_IHxAq-TtLbbzVzcH_jvMd2e94Kh22hnVI9ja_jsgG6AEl3SwmrQoK81090MmPIQUF1-sr2qQnRqGc-EPo1GXp6O6W6tLRNuHcO1qHWybgt9TMq3qxpuDM_TcbTPCJAsmgruFT6bykgP_feH1P7m--_fz6PeqaN0R1wrJllMUqL7KMFYn2PC4ynTooKxAGBS2vnbC5ULGVUoR68d4L7zIjU5MqnoFx6ph9IK_LqvTHhDoTSuBwI7VTaW65MYVjHkqHM-s5cyfkYjuVM2yOEPHQpa9Wi1k_mSfkY7ses7qt4jEDknGO5T79h7_PyFsQpS637BMZFIAG_5m8sc_L-eLpvLE6PMeT0Qt3CdvV
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Combination+of+serum+PSA+assay%2C+multi-parametric+MRI+and+targeted+prostate+biopsy+for+prostate+cancer+screening+in+Nanjing&rft.jtitle=Zhonghua+nan+ke+xue&rft.au=Liang%2C+Jing&rft.au=Zhao%2C+Xiao-Zhi&rft.au=Shi%2C+Jing-Yan&rft.au=Qiu%2C+Xue-Feng&rft.date=2019-09-01&rft.issn=1009-3591&rft.volume=25&rft.issue=9&rft.spage=815&rft_id=info%3Apmid%2F32233209&rft_id=info%3Apmid%2F32233209&rft.externalDocID=32233209
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1009-3591&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1009-3591&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1009-3591&client=summon